No abstract

Trust, as a key element of security, has a vital role in securing vehicular ad-hoc networks (VANETs). Malicious and selfish nodes by generating inaccurate information, have undesirable impacts on the trustworthiness of the VANET environment. Obstacles also have a negative impact on data trustworthiness by restricting direct communication between nodes. In this study, a trust model based on plausibility, experience, and type of vehicle is presented to cope with inaccurate, incomplete and uncertainty data under both line of sight (LoS) and none-line of sight (NLoS) conditions. In addition, a model using the k-nearest neighbor (kNN) classification algorithm based on feature similarity and symmetry is developed to detect the NLoS condition. Radio signal strength indicator (RSSI), packet reception rate (PDR) and the distance between two vehicle nodes are the features used in the proposed kNN algorithm. Moreover, due to the big data generated in VANET, secure communication between vehicle and edge node is designed using the Cuckoo filter. All obtained results are validated through well-known evaluation measures such as precision, recall, overall accuracy, and communication overhead. The results indicate that the proposed trust model has a better performance as compared to the attack-resistant trust management (ART) scheme and weighted voting (WV) approach. Additionally, the proposed trust model outperforms both ART and WV approaches under different patterns of attack such as a simple attack, opinion tampering attack, and cunning attack. Monte-Carlo simulation results also prove validity of the proposed trust model.

No abstract

No abstract

BackgroundOnychomycosis is one of the most common and recurrent dermatological diseases worldwide. The antimycotic activity of prescribed medications varies according to the causative agents, and treatment failure rates exceeding 30%. This study aimed to assess the epidemiological profile of onychomycosis in Iran. Also, the susceptibilities to conventional and new antifungals were investigated.MethodsIn this descriptive cross-sectional study, during the period of 18 months starting from September 2019 until March 2020, 594 nail specimens were obtained from patients who presented nail changes compatible with a clinical diagnosis of onychomycosis. The patients were referred from different cities, including Tehran, Kermanshah, Arak, Kashan, Rasht, Qom, Urmia, Zahedan, Hamadan, Zanjan, Borujerd, Bushehr, and Yazd. All the samples were subjected to microscopic examination and fungal culture. Fungi identified were confirmed through the PCR-sequencing method. The susceptibility to itraconazole, fluconazole, terbinafine, griseofulvin, posaconazole, ravuconazole, efinaconazole, luliconazole, and tavaborole was evaluated according to the Clinical and Laboratory Standards Institute (CLSI) guidelines, document M38-A2 for filamentous fungi, and document M27-A3 for yeasts.Results594 patients were included. Of these, in 179 cases (30.1%) (95% CI:0.3 ± 0.037) onychomycosis was confirmed. The majority of patients were ≥ 60 years of age (n=58, 32.6%) and female (n=113, 63.1%). Saprophytic fungi accounted for the vast majority of the nail isolates (n=92, 51.4%) (95% CI:0.051 ± 0.0.073), followed by dermatophytes (n=45, 25.1%) (95% CI:0.25 ± 0.063), and yeasts (n=42, 23.5%) (95% CI:0.23 ± 0.061). Diabetes mellitus (77.3%), hypothyroidism (18.2%), and solid tumors (4.5%) were documented as the most prevalent underlying conditions. Antifungal susceptibility testing was performed against 60 fungal isolates (20 each of Candida species, saprophytic fungi, and dermatophytes). Efinaconazole, ravuconazole, and luliconazole were the most active agents against Candida species. Also, luliconazole, posaconazole, and efinaconazole were most potent against dermatophytes. Luliconazole had the greatest antifungal activity against saprophytic fungi.ConclusionsThe prevalence of onychomycosis in Iranian patients was relatively high. LUL exhibited potent antifungal activity against the three groups of fungi tested, determining its broad-spectrum antimycotic activity and its probable use as the first-line therapy for onychomycosis.